脑膜瘤的药物治疗研究进展  

Advances in the study of pharmacological treatments for meningiomas

作　　者：李晓杰 朱思鹏 吴震[1] LI Xiaojie;ZHU Sipeng;WU Zhen(Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100071,China)

机构地区：[1]首都医科大学附属北京天坛医院神经外科,北京100071

出　　处：《肿瘤》2024年第9期905-915,共11页Tumor

摘　　要：脑膜瘤是颅内最常见的原发性肿瘤,其中约20%为高级别肿瘤,术后复发率高,放疗控制效果不佳,需要辅助药物治疗。最开始应用细胞毒性药物,但疗效不佳且不良反应大,随后使用以酪氨酸激酶抑制剂、生长抑素类似物等为代表的靶向药物治疗,脑膜瘤患者的预后得到改善。随着高通量测序等新技术的发展,发现了更多的潜在作用靶点。脑膜瘤内存在抑制性免疫微环境,通过调控淋巴细胞和髓系细胞的功能可挽救肿瘤的内在免疫功能,相关的临床试验正在进行中。本文就脑膜瘤的药物治疗研究进展进行综述,对药物治疗的现状和前景进行讨论和展望。Meningioma is the most common primary intracranial tumor,of which about 20%are highgrade tumors,with a high recurrence rate after surgery and poorly controlled by radiotherapy,requiring adjuvant pharmacological treatment.Cytotoxic drugs were applied at the beginning,but the efficacy was poor with significant side effects.Subsequently,targeted drugs such as tyrosine kinase inhibitors and somatostatin analogs were used for treatment,and the prognosis of meningioma patients was improved.With the development of new technologies such as high-throughput sequencing,more potential targets have been revealed.There exists a suppressive immune microenvironment within meningiomas,and modulation of lymphocytes and myeloid cells can rescue the intrinsic immune function of the tumor,and relevant clinical trials are in progress.This article reviewed the research progress of pharmacological treatment of meningiomas,and the current situation and prospects of drug therapy ware discussed and prospected.

关 键 词：脑膜瘤 细胞毒性药物 靶向治疗 免疫治疗 

分 类 号：R739.45[医药卫生—肿瘤]